FAIRsharing record for: HEP Drug Interactions

This FAIRsharing record describes: Currently 170 million people worldwide are infected with the hepatitis C virus (HCV) and >300 million with hepatitis B (HBV). Although interferon-free combination direct acting antivirals (DAAs) regimens have improved tolerability and efficacy for HCV-infected patients, drug-drug interactions (DDIs) have the potential to cause harm due to liver dysfunction, multiple comorbidities and comedications. This web site was established in 2010 by members of the Department of Pharmacology at the University of Liverpool to offer a resource for healthcare providers, researchers and patients to be able to understand and manage drug-drug interactions.

本FAIRsharing记录所描述的内容如下：目前全球共有1.7亿人感染丙型肝炎病毒（hepatitis C virus, HCV），超过3亿人感染乙型肝炎病毒（hepatitis B virus, HBV）。尽管无干扰素联合直接作用抗病毒药物（direct acting antivirals, DAAs）治疗方案提升了丙型肝炎感染者的治疗耐受性与疗效，但药物相互作用（drug-drug interactions, DDIs）仍可能因肝功能异常、多种合并症及合并用药造成不良后果。本网站由利物浦大学药理学系成员于2010年创立，旨在为医疗服务提供者、研究人员与患者提供可用于了解和管理药物相互作用的资源。